Currently, several antibodies against the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) or programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) signaling pathway are approved for the treatment of various cancers (6). This evidence concerns the gene CTLA4 and cancer.